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In the last 20 years, the cellular and molecular mechanisms of inflammation and thrombosis have been characterised.
These are essentially cell adhesion processes which are regulated by vascular endothelium. Many of the cell adhesion
molecules and leucocyte chemoattractants expressed and generated at sites of inflammation have been sequenced and
cloned. These inflammatory molecules work together in concert to mediate the adhesion between leucocytes, platelets and
vascular endothelium which occurs during the occlusive, thromboembolic, reperfusion and septic complications of
atherosclerotic and diabetic vascular diseases. This review aims to summarise our current understanding of the molecular
basis of these disorders and the therapeutic implications.
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Introduction membrane-bound pro-inflammatory molecules, in par-
ticular, leucocyte-endothelial cell adhesion molecules
(CAM). It also secretes soluble factors which attractThe human body reacts to injurious stimuli by mount-
peripheral blood leucocytes and induce coagulation,ing an inflammatory response. In its acute phase,
thus resulting in the leucocyte recruitment and platelettransvascular shifts of fluid, plasma proteins and leuco-
thrombosis observed at sites of inflammation.cytes occur in the microvasculature of the injured
Inflammatory cytokines are small peptides secretedtissue. Vascular injury induces the activation of both
primarily by activated tissue macrophages and lym-platelets and coagulation proteins which work to-
phocytes in response to injurious stimuli, such asgether to maintain haemostasis. These physiological
endotoxin, immune complexes, physical and chemicalprocesses are intended to neutralise the injurious
injury. Interleukin-1b (IL-1b) and tumour necrosis fac-stimulus, limit tissue injury and initiate healing and
tor a (TNF a) are the main cytokines that mediate therepair, and this was recognised by a surgeon, John
inflammatory response.3 They have a wide range ofHunter, as early as the 19th century.1
actions on different cells but their main effects are toThe importance of vascular endothelium as a regu-
induce the acute-phase reaction and to activate vas-latory organ in immunity and haemostasis has become
cular endothelium, leucocytes, platelets and fibro-well established in the last two decades.2 Normally,
blasts, thus, initiating the cascade of vascular, cellularvascular endothelium is in an “unactivated” state.
and humoral events which together comprise the in-However, at sites of injury and inflammation, endo-
flammatory response.thelium becomes locally “activated”, either by the
In this review, we will focus on the role of non-injurious stimulus itself, or by inflammatory cytokines
lymphoid vascular endothelium, leucocyte-endothelialgenerated in response to the injurious stimulus. Ac-
CAM, chemoattractants, leucocytes and platelets astivated vascular endothelium expresses a number of
the primary molecular and cellular components of
the inflammatory response. The currently understood
molecular mechanisms of atherogenesis and
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thrombosis will also be summarised. We will concludeThe General Infirmary at Leeds, Great George Street, Leeds LS1
3EX, U.K. by discussing possible therapeutic applications.
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Vascular Endothelium regulated by cytoplasmic transcription factors, such
as nuclear factor jB,14 are induced during endothelial
Although a mere cellular monolayer, vascular endo- activation. Thus, endothelial activation is a process
which occurs over a period of hours being dependentthelium contains the entire circulation and forms a
vast surface area of interface between the components on gene expression and de novo protein synthesis. For
example, the endothelial CAM, E-selectin, which isof the circulation (including leucocytes, platelets and
plasma proteins) and all of the body’s tissues. It per- believed to be a “silent” gene under normal cir-
cumstances, is synthesised and expressed by activatedforms a wide variety of functions including the re-
gulation of vascular permeability and vascular tone, endothelial cells, and becomes detectable between 1
and 24 hours after activation.15 In contrast, throm-wound healing, immunity and haemostasis, thus, serv-
ing as a “gatekeeper” for the traffic of water and bogenic mediators, such as histamine and thrombin,
induce endothelial stimulation which occurs rapidlysolutes, bioactive proteins and lipids, and peripheral
blood leucocytes, between the circulation and inter- (within minutes) and independently of gene ex-
pression and protein synthesis. P-selectin is expressedstitial tissues.
As a regulatory organ, vascular endothelium serves transiently during endothelial stimulation.
both sensory and effector functions, bearing receptors
for a wide range of cytokines, chemotactic and vaso-
active peptides and lipids, and CAM, as well as itself
Regulatory role in haemostasisbeing able to express and elaborate many of these
immunomolecules. Selective spatial and temporal ex-
Unactivated endothelial cells are remarkable in beingpression of these molecules by vascular endothelium
the only cells known to be actively antithrombotic.provides a means by which inflammatory and throm-
Firstly, they form an insulating barrier between throm-botic processes may be regulated. Vascular endo-
bogenic subendothelial matrix components, and plate-thelium continually senses chemical, physical and
lets and coagulation proteins in the circulation.biomechanical alterations in its surroundings and
Secondly, unactivated endothelial cells secrete pro-transduces these into biological responses. For ex-
stacyclin and nitric oxide which inhibit platelet ag-ample, changes in blood flow have been shown to
gregation,4,5 as well as protein S16 and tissueinduce alterations in the synthesis of several vascular
plasminogen activator17 which inhibit coagulation.endothelial-dependent factors, such as prostacyclin,
However, activated vascular endothelium is pro-nitric oxide and intercellular adhesion molecule-1.4–6
thrombotic. It secretes tissue factor which triggers the
coagulation cascade18,19 and expresses increased levels
of plasminogen activator inhibitor-1 which inhibits
Regulatory role in leucocyte traffic fibrinolysis.20 Vascular injury may expose sub-
endothelial matrix components such as collagen and
In vivo studies in leucocyte-endothelial adhesion in von Willebrand factor (vWF) which promote and sup-
the microcirculation and in vitro studies performed port platelet adhesion and aggregation.
under flow conditions designed to simulate micro- Thus, at rest, vascular endothelium maintains blood
vascular blood flow indicate that unactivated vascular in its fluid form but, in response to vascular injury, it
endothelium is hypo-adhesive for leucocytes, by virtue becomes locally prothrombotic to seal off rapidly any
of minimal expression of leucocyte-endothelial CAM.7 breach in the integrity of the vasculature.
However, stimuli such as endotoxin,8 inflammatory
cytokines,3 histamine and thrombin9 induce local endo-
thelial activation or stimulation. Activated or stimu-
lated vascular endothelium is hyperadhesive for Leucocyte-endothelial Cell Adhesion Molecules
leucocytes due to upregulated expression of CAM
such as E-selectin,10 intercellular adhesion molecule- The histological hallmark of acute inflammation is the
infiltration of interstitial tissues by peripheral blood111 and P-selectin.9 Additionally, activated endothelial
cells express and secrete chemotactic factors such as leucocytes that consists in the early phases pre-
dominantly of neutrophils and, later on, mononuclearplatelet-activating factor12 and interleukin-813 which
may activate adherent leucocytes and direct their mi- leucocytes. The ability of peripheral blood leucocytes
to extravasate at sites of inflammation was describedgration across the endothelium and within the in-
flamed tissues. over a century ago,21 but only in the past decade have
the molecules responsible for leucocyte adhesion andMultiple inflammatory response genes which are
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transendothelial migration (also called diapedesis, cytes.37 Neutrophils and monocytes bear high surface
levels of L-selectin that is lost or shed by proteolyticemigration) been identified and cloned, and their
mechanisms of action defined.22–24 cleavage on contact with activated endothelium or
chemoattractants.27,38 A basal level of shedding appearsLeucocyte-endothelial cell adhesion molecules
(CAM) are proteins expressed on the surface of leuco- to result in high levels of functionally active L-selectin
in plasma39 which may reach levels sufficient to par-cytes and platelets and the surface of vascular endo-
thelium. They mediate the adhesive interactions tially inhibit leucocyte-endothelial adhesion.40 How-
ever, in vitro, L-selectin shedding per se neitherbetween circulating leucocytes and endothelium lead-
ing to leucocyte recruitment into tissues, and between enhances nor inhibits neutrophil-endothelial adhesion
and transmigration.41platelets and endothelium resulting in thrombosis. The
role of CAM in leucocyte trafficking in health and CD62P or P-selectin (“P” for platelet) is normally
not expressed but sequestered in intracellular storagedisease has been established by in vitro experiments
with cultured vascular endothelium and isolated granules in vascular endothelial cells (in Weibel–
Palade bodies) and platelets (in a-granules).9 Throm-leucocytes25–27 and by in vivo experiments using animal
models.28,29 The generation of function-blocking mono- bogenic and inflammatory mediators such as
histamine, thrombin, and leucotrienes C & D induceclonal antibodies against individual CAM has enabled
the various steps of leucocyte-endothelial adhesion to rapid translocation of P-selectin to the surface of plate-
lets and vascular endothelial cells. In vitro, the ex-be characterised. More recently, experiments using
genetically-engineered mutant mice lacking one or pression of P-selectin is rapid and short lived
(expressed then downregulated within minutes).more CAM (“knockout mice”) have further clarified
their respective roles in leucocyte trafficking and im- CD62E or E-selectin (“E” for endothelial) is ex-
pressed exclusively by activated vascular endothelialmunity.30–33 Furthermore, the importance of CAM in
host defence is vividly illustrated by two rare auto- cells.15 Induction of the E-selectin gene in cultured
human umbilical vein endothelial cells by in-somal recessively inherited diseases, leucocyte ad-
hesion deficiency (LAD) Types I & II.34,35 LAD I patients flammatory stimuli, such as endotoxin, IL-1b or TNF-
a, induces gene transcription and surface expressionhave deficient neutrophil diapedesis and phagocytosis
due to molecular defects in their leucocyte integrins. of the E-selectin protein which is detectable within an
hour of endothelial activation. In vitro, peak E-selectinSimilarly, LAD II patients exhibit deficient neutrophil
adhesion due to a metabolic defect in the synthesis of expression occurs around 4–6 h and becomes un-
detectable after 12–24 h. However, more prolongedselectin ligands. LAD patients are markedly im-
munodeficient and suffer from severe, recurrent and expression of E-selectin may exist in vivo in chronic
inflammatory diseases.42,43often fatal bacterial infections.
To date, endothelial-leucocyte CAM have been clas- The physiological counter-receptors of selectins have
not been fully characterised, but they appear to besified according to structural homology into 4 families:
the selectins, integrins, mucin-like CAM and the im- carbohydrate structures presented by glycoproteins on
the surface of vascular endothelium, leucocytes andmunoglobulin superfamily (Table 1). The salient char-
acteristics only of these CAM will be discussed below platelets.24,44
as more detailed reviews already exist.22–24,36
Selectins Mucin-like proteins
Selectins are transmembrane glycoproteins expressed P-selectin glycoprotein ligand-1 (PSGL-1) is the best
characterised selectin counter-receptor.45,46 PSGL-1 isby leucocytes, and activated endothelium and plate-
lets. Their primary function appears to be to mediate present on neutrophils, monocytes and lymphocytes
and binds L-selectin, E-selectin and P-selectin.47–49the initial attachment and rolling (discussed below)
adhesive interactions that occur under patho- Neutrophil–neutrophil adhesive interactions that
occur during neutrophil aggregation as well as duringphysiological conditions of blood flow between leuco-
cytes and postcapillary venular endothelium at sites initial attachment and rolling (discussed below) of
neutrophils on activated vascular endothelium areof inflammation.24 There are three members of the
selectin family. mediated by PSGL-1–L-selectin bonds.47,50 Current
evidence suggests that another ligand for L-selectinCD62L or L-selectin (“L” for leucocyte) is con-
stitutively expressed on the surface of most leuco- may be expressed by activated non-lymphoid vascular
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Table 1. Endothelial-leucocyte cell adhesion molecules.
Family Members Cluster designation Cellular distribution Counter-receptor/ligand
Selectins E-selectin CD62E Endothelium PSGL-1, ?other carbohydrate-
bearing structure(s) on leucocytes
L-selectin CD62L Leucocytes PSGL-1, ?inducible carbohydrate-
bearing structure(s) on
endothelium
P-selectin CD62P Endothelium, platelets PSGL-1, ?other carbohydrate-
bearing structure(s) on leucocytes
Mucin-like PSGL-1 CD162 All blood leucocytes E-, L- and P-selectin
b1 integrins a4b1 CD29 Monocytes, lymphocytes VCAM-1
b2 integrins LFA-1 CD11a/CD18 Leucocytes ICAM-1, ICAM-2, ICAM-3
Mac-1 CD11b/CD18 Monocytes, neutrophils ICAM-1, fibrinogen
p150,95 CD11c/CD18 Monocytes, neutrophils ?
b7 integrins a4b7 Lymphocytes VCAM-1
Ig ICAM-1 CD54 Endothelium, leucocytes, LFA-1, Mac-1
epithelial cells, fibroblasts,
other cell lines
ICAM-2 CD102 Endothelium LFA-1
ICAM-3 CD50 Leucocytes LFA-1
VCAM-1 CD106 Endothelium, smooth muscle a4b1, a4b7
cells
PECAM-1 CD31 Endothelium, leucocytes, PECAM-1
platelets
endothelium, although it has yet to be identified.24,51 which have CD18 as their common b chain: lympho-
cyte function associated antigen-1 (LFA-1) or aLb2Other mucin-like proteins such as GlyCAM-1, CD34
(CD11a/CD18), Mac-1 or aMb2 (CD11b/CD18), andand ESL-1, which bind selectins, have been described
p150,95 or aXb2 (CD11c/CD18). To date, neutrophilsin animal models, but except for CD34 these have not
are known to express only b2 integrins while mono-been shown to be counter-receptors for selectins in
cytes and lymphocytes express both b1 and b2 inte-humans.24
grins.36
Unactivated neutrophils express high surface levels
of LFA-1 and Mac-1 but minimal amounts of p150,95.53
Leucocyte integrins Mac-1 is also stored within intracellular peroxidase-
negative granules.54 On activation by inflammatory
Integrins are transmembrane glycoproteins widely ex- mediators such as chemoattractants, in vitro, the sur-
pressed on many cells.34,52 They are heterodimers of face expression of Mac-1 is upregulated several-fold
an a subunit non-covalently linked to a b subunit and by translocation from cytoplasmic granules while that
have been classified into subfamilies according to their of LFA-1 remains relatively unchanged.55–57 However,
b chain (8 b chains have been identified to date). these newly-expressed Mac-1 molecules may not all
The main integrin subfamilies relevant to the role be functionally competent, as further conformational
of leucocytes and platelets in inflammation and throm- change with the expression of activation neo-epitopes
bosis are b1, b2, b3 and b7. b1 integrins are expressed appears to be necessary for ligand binding. Expression
by a wide variety of vascular and non-vascular cells, of activation neo-epitopes which confer the ability to
the b1 chain (CD29) combining with a variety of a bind ligand has been described for both LFA-1 and
chains. b3 integrins or cytoadhesins are expressed by Mac-1.55,58
platelets, endothelial cells and smooth muscle cells LFA-1 counter-receptors include intercellular ad-
(the b3 chain being designated CD61). b1 and b3 integ- hesion molecule-1 (ICAM-1), ICAM-2 and ICAM-359–61
rins will be briefly discussed later in the context of while Mac-1 binds to ICAM-1, fibrinogen55,62 and op-
platelets and thrombosis. However, the integrin sub- sonic complement fragment (iC2b).63 Mac-1 is also
family most relevant to endothelial-leucocyte adhesion believed to mediate the binding of neutrophils to
is the b2 (CD18) or leucocyte integrin subfamily. plastic and glass, and aggregation with other neutro-
b2 integrins are expressed exclusively by leucocytes. phils.53 The counter-receptor(s) of p150,95 are less cer-
tain, but it may be a complement receptor.64The b2 integrin subfamily has three members all of
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Immunoglobulin superfamily CD31 expression is not upregulated by inflammatory
cytokines, although its distribution on the surface of
endothelial cells may be altered by interferon c andCAM belonging to the immunoglobulin (Ig) super-
TNFa.79,80 It also mediates adhesion between myeloidfamily consist of cell surface proteins which are related
cells (neutrophils and monocytes) and platelets as wellstructurally by possessing varying numbers of Ig-like
as between myeloid cells and vascular endothelium.domains. There are five members of the Ig-like family
It appears to be important in mediating neutrophilwhich mediate endothelial-leucocyte adhesion: in-
and monocyte transmigration between intercellulartercellular adhesion molecule-1 (ICAM-1), ICAM-2,
junctions of normal and activated vascular endo-ICAM-3, vascular cell adhesion molecule-1 (VCAM-
thelium.81,82 Recently, CD31 has been shown to undergo1) and platelet-endothelial cell adhesion molecule-1
adhesion to the integrin aVb3.83(PECAM-1).
ICAM-1 (CD54) is widely expressed by many cell
Platelet glycoproteinstypes including vascular endothelium, fibroblasts, epi-
thelial cells, skeletal myocytes, and some leucocytes
Platelets are crucial to the body’s normal inflammatorybut not neutrophils.65 It is constitutively expressed at
response because of their ability to form haemostaticlow levels by vascular endothelium but its expression
platelet plugs very rapidly at sites of vascular injury.is upregulated several-fold by endotoxin and in-
They also play an important role in initiating healingflammatory cytokines.11 Its counter-receptors include
processes, by virtue of the growth and chemotacticLFA-1, Mac-1, rhinovirus66 and Plasmodium falciparum.67
factors stored in their alpha granules and released onSoluble ICAM-1 detected in human plasma39 has been
activation. The surfaces of these tiny non-nucleatedproposed as a means by which the body modulates
cells are densely decorated with b1 and b3 integrinsICAM-1 mediated adhesion (by binding to its counter-
and other platelet glycoproteins (gp) which mediatereceptors such as LFA-1 and Mac-1 on leucocytes).
the two platelet reactions that are crucial for normalHowever, the concentrations of soluble ICAM-1 neces-
haemostasis, namely, platelet adhesion and plateletsary to competitively inhibit ICAM-1–LFA-1 adhesion
aggregation. Platelets adhere to subendothelial matrixexceed those normally found in plasma and therefore,
proteins exposed by vascular injury (platelet ad-it is unlikely that soluble ICAM-1 would antagonise
hesion). Then, on activation, by the process of plateletICAM-1 mediated adhesion in vivo.68
adhesion and/or by agonists such as adenine di-
ICAM-2 (CD102) is constitutively expressed by vas- phosphate (ADP), adrenaline and thrombin, more
cular endothelium and some mononuclear leucocytes. platelets are recruited and begin to adhere to each
Its level of expression by vascular endothelium is other (platelet aggregation) and to form a haemostatic
not cytokine-inducible.69 ICAM-3 (CD50), on the other plug onto which fibrin may be deposited. Leucocyte
hand, is highly expressed on leucocytes but not vas- recruitment mediated by P-selectin appears to be in-
cular endothelium.61 Both ICAM-2 and ICAM-3 have volved in this process of fibrin deposition.84
been shown to bind LFA-1 but their role in leucocyte- Platelet adhesion is mediated by a2b1 (binds col-endothelial adhesion remains uncertain.60,61,69 lagen), a5b1 (binds fibronectin), a6b1 (binds laminin)
VCAM-1 (CD106) is expressed mainly by vascular and aIIbb3 (also called, gpIIb/IIIa) as well as other
endothelium but may also be expressed by vascular glycoproteins, such as gpIb (binds vWF).85,86 Platelet
smooth muscle cells, dendritic cells and synovial aggregation, however, is mediated exclusively by the
cells.70–72 VCAM-1 expression is focally upregulated by b3 integrin, aIIbb3 (gpIIb/IIIa). gpIIb/IIIa binds to a
inflammatory and atherogenic stimuli such as IL-1b, number of soluble proteins including fibrinogen and
interleukin-4 and lysophosphatidylcholine (a com- vWF but becomes functional (by “uncovering” of lig-
ponent of atherogenic lipoproteins).73–75 Counter-re- and binding sites which lie hidden on unactivated
ceptors identified for VCAM-1 to date include the b1 platelets) only on platelet activation.87,88 Fibrinogen
and b7 integrins, VLA-4 (a4b1) and a4b7.76,77 Neutrophils and vWF form crossbridges between gpIIb/IIIa
do not express b1 and b7 integrins and cannot bind to molecules on adjacent platelets, thereby resulting in
VCAM-1. platelet aggregation. Blockade of gpIIb/IIIa totally
PECAM-1 (CD31) is constitutively expressed by vas- inhibits platelet aggregation.
cular endothelium, neutrophils, monocytes, some lym-
phocytes and platelets.23 Its expression on vascular Chemoattractants
endothelium is characteristic, being concentrated at
intercellular junctions78 where it mediates adhesion The proces of “chemotaxis” may be defined as the
unidirectional locomotion of a cell in response to a(CD31–CD31) between vascular endothelial cells.
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Table 2. Leucocyte chemoattractants.
Family Member Source Target cell(s)
“Classical” C5a Plasma protein cleavage product Monocyte, neutrophils, basophils, eosinophils
fMLP Bacteria Monocytes, neutrophils
PAF Leucocytes Monocytes, neutrophils, eosinophils
LTB4 Leucocytes Neutrophils
C-X-C chemokines IL-8 Most somatic cells Neutrophils, basophils
GRO-a, -b, -c Most somatic cells Neutrophils, basophils
IP-10 Most somatic cells Monocytes
PF4 Platelets Monocytes, neutrophils
C-C chemokines MCP-1, -2, -3 Most somatic cells Monocytes, basophils, specific lymphocyte subsets
MIP-1a Most somatic cells Monocytes, basophils, eosinophils, specific lymphocyte
subsets
MIP-1b Most somatic cells Monocytes, specific lymphocyte subsets
RANTES Most somatic cells Monocytes, basophils, eosinophils, specific lymphocyte
subsets
concentration gradient of a chemoattractant substance. basophils, eosinophils and monocytes. fMLP, a bac-
terial oligopeptide, has also been shown to induceLeukocytes, in particular, have long been observed to
exhibit chemotaxis.21 Chemical substances or micro- chemotaxis in neutrophils and monocytes.101 It should
be noted that these chemoattractants neither exhibitorganisms placed at extravascular sites, such as the
anterior ocular chamber or the peritoneal cavity, in- specificity of chemoattraction for any particular leuco-
cyte subset nor are their biological activities confinedduce the accumulation of large numbers of peripheral
blood leucocytes at these sites as part of an in- to inducing leucocyte chemotaxis alone. PAF, as its
name suggests, is a potent activator of platelets andflammatory response.
To date, a wide range of chemotactic molecules have leucocytes as well as having vasoactive properties.99
been identified which attract and activate leuco-
cytes.89–91 Furthermore, specific chemotactic receptors
Chemokinesfound on the leucocyte surface have now been
cloned.92,93 Presumably, by using these receptors leuco- Chemokines (contraction of chemotactic cytokines) arecytes are able “to sense” small concentration dif- a family of small pro-inflammatory peptides withferences of chemotactic substances across their potent leucocyte chemoattractant and activating prop-diameter and then crawl in the direction of increasing erties.90,102 To date, they have been classified into twoconcentration.94 main subfamilies according to amino acid sequence,
their gene locus and the leucocyte subset on which
they primarily exert chemotactic activity (Table 2). This
specificity of chemoattraction of a particular leucocyte“Classical” chemoattractants
subset is a key feature of chemokines, in contrast to
“classical” chemoattractants discussed above.A variety of bioactive peptides and lipids of endo-
genous and exogenous origin were identified in the Chemokines are mostly inducible molecules, that is,
produced and secreted only on cellular activation by1970s and found to be leucocyte chemoattractants.
Activated neutrophils produce an oxidised phos- endotoxin or inflammatory cytokines or in response
to agents such as crystals and viruses.90 Induction ofpholipid leucotriene B4 (LTB4),95 as well as an ether
phospholipid, platelet-activating factor (PAF),96,97 both secretion of interleukin-8 (IL-8) and monocyte chemo-
attractant protein-1 (MCP-1) has been described in aof which are chemotactic for neutrophils. PAF-like
molecules are also generated by activated vascular wide variety of cells while a small group of C-X-C
chemokines have only been found preformed andendothelium in a membrane-bound form.98 PAF, apart
from being a leucocyte chemoattractant, has diverse stored in platelet granules. Apart from chemotaxis,
chemokines also induce leucocyte activation. IL-8 andbiological activities including enhanced adhesion of
platelets and leucocytes to endothelium, vaso- MCP-1 induce degranulation and the respiratory burst
in neutrophils and monocytes respectively.103,104 Ad-constriction and bronchoconstriction.96,99 Both C5a
anaphylatoxin, a plasma peptide generated by ditionally, while IL-8 induces PAF secretion by neutro-
phils,105 MCP-1 induces IL-1 and IL-6 secretion bycomplement activation, and its cleavage product,
C5ades arg, are potent chemoattractants for neutrophils,100 monocytes.106
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C-X-C (or a) chemokines are so-called because they In summary, it appears that chemoattractants con-
centrated in extravascular tissue spaces induce leuco-have an intervening amino acid between the first two
of the four conserved cysteines at their N-terminus. cyte recruitment, while high levels of intravascular
chemoattractant tend to attenuate leucocyte ex-They are encoded for on chromosome 4.107 C-X-C
chemokines include IL-8, epithelial-derived neutrophil travasation.102,122
attractant-78 (ENA-78), growth-related cytokine-a
(GRO-a), interferon c-inducible protein-10 (IP-10) and
platelet factor-4 (PF4). C-X-C chemokines (IL-8, GRO,
The Leucocyte-endothelial Adhesion CascadeENA-78) are primarily neutrophil chemoattractants.
However, IP-10 attracts monocytes but not neutro-
The recruitment of leucocytes is precisely regulatedphils108 while PF4 can attract both neutrophils and
by vascular endothelium, which, on activation, pres-monocytes.109 IL-8 can also attract basophils110 and by
ents an adhesive surface to circulating leucocytes.an indirect mechanism, T-cells.
The process of adhesion and diapedesis then involvesC-C (or b) chemokines, on the other hand, do not
sequential binding of different CAM to their counter-have an intervening amino acid between their first
receptors in a so-called “adhesion cascade”. Generally,two amino-terminal cysteine residues. They are en-
leucocyte CAM are expressed constitutively, whilecoded for on chromosome 17109 and are primarily
vascular endothelium express CAM on activation. Inmonocyte and T-cell chemoattractants.111,112 C-C chemo-
vivo studies, particularly using intravital microscopy,kines include MCP-1, MCP-2, MCP-3, monocyte in-
indicate that leucocyte adhesion and diapedesis mostlyflammatory protein-1a (MIP-1a), MIP-1b and RANTES
occurs in post-capillary venules rather than in ar-(regulated on activation, normal T expressed and se-
terioles or capillaries.123,124 This may, in part, be due tocreted).
higher blood flow rates in arterioles, but may also
be related to intrinsic differences in the venular and
arteriolar endothelial expression of CAM necessary
Mechanisms of chemoattractant function for adhesion under conditions of flow.
The individual steps of the adhesion cascade became
In vitro assays of chemotaxis113,114 suggest that a “dif- apparent from direct observation of the dynamics
fusion barrier” located between leucocytes and the of leucocyte-endothelial adhesion, by both intravital
“reservoir” of chemoattractant substance is necessary videomicroscopy28,29 as well as by using in vitro flow
to establish a concentration gradient. Leucocytes sense systems in which the pathophysiological and hy-
and crawl “up” this gradient in the direction of in- drodynamic conditions of leucocyte adhesion under
creasing concentration. In contrast, leucocytes placed fluid flow at the luminal surface of vascular endo-
in an environment of uniform chemoattractant con- thelium were simulated.27,125 The five main steps of
centration undergo enhanced random and dir- the adhesion cascade are: (1) random contact and
ectionless movements called “chemokinesis”.115 margination, (2) initial attachment (or tethering) and
In vivo, vascular endothelium, the vessel wall, and rolling, (3) stable arrest and adhesion, (4) trans-
the interstitial tissue spaces may serve the function of migration (or diapedesis), (5) interstitial migration and
being a “diffusion barrier” that establishes a con- carrying out effector functions (Fig. 1).
centration gradient. Blood flow, by dilution and fluid
motion, would actively tend to lower the concentration
of chemoattractant in the intravascular compartment.
Moreover, red blood cells and venous endothelium Margination (Fig. 1A)
bear large numbers of a “scavenger receptor” for
chemokines,116,117 which would tend to lower the con- This first step in leucocyte-endothelial adhesion in vivo
is a purely random and haemodynamic phenomenoncentration of functional chemoattractant within the
circulation. However, these factors are absent in the that does not involve the formation of any cell adhesion
bonds. Normally, blood flowing through postcapillaryextravascular/interstitial compartment where chemo-
attractants may accumulate. High levels of IL-8, for venules may be observed to form a central cellular
zone consisting of red blood cells and leucocytes andexample, have been found sequestered in extravascular
tissue compartments such as infected joint and pleural a peripheral cell-free zone.126 At sites of inflammation,
they tend to be pushed away from the centre streamcavities.118–120 IL-8 has been reported to be secreted in
a polarised fashion into the extravascular com- towards the endothelial surface (marginated) by a
number of haemodynamic factors.partment.121
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Smaller-sized red blood cells travelling at greater other neutrophils already stably adherent to the endo-
thelial surface in vitro.50,135 Neutrophil–neutrophil roll-velocities tend to marginate leucocytes.127 Leucocytes
from smaller tributaries feeding into the side of larger ing and aggregation may be a means of amplifying
the rate of recruitment of neutrophils at sites of in-venules are pushed by the prevailing blood flow in
the larger vessel towards its sidewalls.123 During in- flammation.50,136 Free-flowing neutrophils may be seen
to tether to activated vascular endothelium and thenflammation, acute phase proteins in the circulation
increase the viscosity of the blood and may induce the to form linear aggregates and discrete foci of rol-
ling neutrophils.27,50 These neutrophil–neutrophilformation of erythrocyte aggregates. This, along with
the slowing of blood flow in the microcirculation at adhesive interactions are mediated by L-selectin
binding to PSGL-1. Leucocytes carry both L-selectinsites of inflammation due to vasodilation, will also
tend to marginate leucocytes.128 as well as PSGL-1 preferentially on the tips of their
microvilli, ideally placed for mediating initialThe release of vasodilators, e.g. histamine and
prostaglandins, during the inflammatory response attachment and rolling on other neutrophils or vas-
cular endothelium.46,137may increase blood flow and, therefore, the delivery
of leucocytes to sites of inflammation. In the presence In summary, a selectin-mediated step is required for
leucocyte-endothelial adhesion to occur and culminateof tissue injury, upregulated CAM expression may
result in adhesive interactions between the marginated in successful leucocyte recruitment, under patho-
physiological conditions of fluid flow.leucocytes and the hyperadhesive vascular endothelial
surface, thus initiating the adhesion cascade.
Stable arrest and adhesion (Figure 1C)
Rolling (Figure 1B) Rolling leucocytes having decelerated begin to form
more stable adhesion bonds and, thus, “arrest” in
Leucocytes in postcapillary venules at sites of in- stationary positions on the endothelial surface despite
flammation may be observed to decelerate and “roll”. the prevailing shear forces of fluid flow. A necessary
This is the resultant of transient adhesion bonds being prerequisite for this step to occur successfully appears
repeatedly formed and broken, between endothelial to be integrin activation. Chemokines (e.g. IL-8) and
and leucocyte CAM under the prevailing hydro- other chemoattractants, such as PAF,26 are generated at
dynamic forces of fluid flow. inflammatory sites.138 Leucocytes rolling on activated
This “rolling” behaviour of leucocytes contacting endothelium may be exposed to chemokines/chemo-
the luminal surface of activated vascular endothelium attractants or other stimuli which activate the leucocyte
is mediated primarily by the selectins,24,129 although integrins rendering them competent to bind ICAM-1
VCAM-1 has also been shown to mediate leucocyte and VCAM-1. Thus, stable arrest in neutrophils and
rolling.130 The shear forces at the luminal surface of monocytes is mediated by b2 integrin–ICAM-1 ad-
postcapillary venules are around 1–5 dynes/cm2 131,132 hesion.27,29 Additionally, mononuclear leucocytes also
and require the formation of selectin-mediated bonds employ b1 and b3 integrins to bind to VCAM-127 and
to “capture” marginated leucocytes being swept along stably adhere to activated vascular endothelium.
by blood flow. At lower flow rates (shear rate Z0.6
dynes/cm2), L-selectin appears to become less efficient
at mediating rolling,133 and then other adhesion mech-
anisms, such as b2 integrin-ICAM-1, may function in Transendothelial migration/diapedesis (Figure 1D)
mediating initial attachment and rolling.125,134
Neutrophils have been shown to undergo rolling on Stably adherent leucocytes then begin to flatteen and
spread on the luminal surface and extend pseudopodsboth activated vascular endothelium as well as on
Fig. 1 (opposite) (A) Margination is largely a haemodynamic phenomenon and does not depend on any adhesion bonds. (B) Initial
attachment and rolling is mediated by selectins (e.g. L-selectin) binding their counter-receptors (e.g. PSGL-1). Neutrophils roll and
decelerate on both activated endothelium as well as other adherent neutrophils. (C) Stable adhesion is mediated by adhesion between
integrins (e.g. Mac-1 and a4b1) present on the leucocyte surface and Ig (e.g. ICAM-1 and VCAM-1) on the surface of activated endothelium.
(D) Transendothelial migration is mediated by CD31–CD31 adhesion between stably adherent leucocytes and endothelium as well as
integrin–Ig bonds. Chemokines may promote diapedesis by activating leucocyte integrins or inducing chemotaxis. (E) Chemokines
sequestered in extravascular tissue spaces may direct the interstitial migration of transmigrated leucocytes and induce leucocyte activation.
Extravasated leucocytes may in turn generate more chemoattractants, thereby amplifying the recruitment process.
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towards intercellular borders. This process which is C5a produced during myocardial ischaemia-
reperfusion injury mediates recruitment of neutrophilmediated by leucocyte integrins engaging ICAM-1
and/or VCAM-1 appears to involve the coordinated which in turn, on activation, may generate IL-8, PAF
and LTB4, thus inducing further neutrophil re-formation and breaking and then re-formation of ad-
hesion bonds as the leucocyte “crawls” across the cruitment.144,145 Similar mechanisms may exist for
monocytes and other leucocytes.146 Furthermore, thereendothelial surface towards the intercellular border
without being swept away by fluid flow. At the in- appears to be a system of networking between different
cells via cytokines and other chemoattractants to amp-tercellular border leucocytes extend pseudopods be-
tween endothelial cells and transmigrate into the lify the inflammatory response. During Gram-negative
pulmonary sepsis, alveolar macrophages, on activationextravascular spaces. The process of neutrophil and
monocyte transmigration or diapedesis between the by endotoxin, secrete inflammatory cytokines which
then act on pulmonary fibroblasts to generate IL-8,intercellular junctions of normal and activated vascular
endothelium has been shown to be mediated in part while endotoxin alone did not induce significant IL-8
secretion by pulmonary fibroblasts.141by both integrin–ICAM-1 or integrin–VCAM-1 as well
as CD31–CD31 adhesive interactions.25,81,82 The relative
importance of each mechanism remains to be further
clarified for different leucocyte subsets. For example,
Endothelial-mediated Mechanisms ofsome leucocytes (memory T-cells) do not express CD31
Atherosclerosisand yet are able to transmigrate successfully.139 Chemo-
attractants may promote diapedesis by inducing
The importance of atherosclerosis as a leading causechemotaxis or by integrin activation.
of morbidity and mortality is undisputed. Athero-
sclerosis is thought to be an excessive inflammatory-
fibroproliferative response to chronic injury in sus-
Interstitial migration and effector functions (Figure 1E) ceptible arteries.147 It appears to be the result of com-
plex interactions between arterial endothelium and
At sites of inflammation, chemoattractants are gen- smooth muscle cells, and surrounding physical and
erated and then sequester in interstitial and ex- biochemical factors such as circulating leucocytes and
travascular tissue spaces, being secreted by tissue platelets, proteins and lipids carried in plasma and
macrophages and non-vascular cells such as fibro- haemodynamic forces.2
blasts.119,140–142 Chemokines entering the circulation are The earliest anatomical lesion of atherosclerosis is a
carried away by blood flow and become functionally subendothelial accumulation of lipid-laden macro-
inactive by binding to scavenger receptors found on the phages called the “fatty streak”. An even earlier cellu-
surface of red blood cells and venular endothelium.143 lar event during atherogenesis is the increased
Functionally active chemokines and other chemo- adherence of peripheral blood monocytes to the endo-
attractants thus tend to localise in extravascular tissue thelium of large arteries at sites which later develop
compartments and from there induce chemotaxis and fatty streaks.148 In a rabbit model of atherogenesis,
activation of extravasated leucocytes, which then are recruitment of peripheral blood monocytes is preceded
induced to carry out their respective effector functions by focal VCAM-1 expression.149 VCAM-1, expressed
such as cytokine secretion, phagocytosis and de- by activated arterial endothelium, mediates monocyte-
granulation. endothelial adhesion,27 and may be one of the earliest
molecular markers of atherosclerosis. At these sites,
fatty streaks develop and later progress into fibro-fatty
atherosclerosis plaques containing monocytes and T-Mechanisms of Amplifying the Inflammatory
Response lymphocytes.150 Other CAM, namely, ICAM-1, CD31,
and P-selectin, have also been shown to be expressed
A number of mechanisms exist which seem to both by human atherosclerotic plaques151,152 and each of
these is capable of mediating leucocyte-endothelialregulate and amplify the inflammatory response. L-
selectin–PSGL-1-mediated adhesion and aggregation adhesion.27,82,153
Hyperlipidaemia per se results in a number of pro-between neutrophils may be a means of localising and
amplifying the numbers of neutrophils “captured” to atherogenic changes in the vessel wall. It induces
endothelial activation and the expression of MCP-1,adhere to activated endothelium at sites of in-
flammation.50 Inflammatory mediators may be se- a monocyte chemoattractant.154 Hyperlipidaemia also
stimulates monocyte production of IL-1b,155,156 which inquentially generated by different cells. For example,
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turn induces further endothelial activation and MCP-1 these cell adhesion processes and a number of mo-
lecular sites present themselves as being potentialexpression. IL-1b may also act as a growth factor for
smooth muscle cells.157 Furthermore, cytokine ac- targets (Table 3). Antagonism of the cytokines which
drive the inflammatory response may reduce the se-tivation of endothelium and smooth muscle cells has
been shown to induce the expression of macrophage verity of tissue damage locally and dampen un-
desirable systemic effects. Disruption of some or allcolony stimulating factor,158 a cytokine involved in the
growth and maturation of monocyte-macrophages. of the steps of the endothelial-leucocyte adhesion cas-
cade, by blockade of CAM and/or chemoattractants,Diabetics develop premature and florid atherosclerosis
and a possible mechanism for this may involve the may be a means of controlling leucocyte recruitment
in inflammatory diseases. Instead of blockade at theformation of advanced glycation endproducts in the
vascular wall in response to chronic hyperglycaemia. level of extracellular protein, it may be possible to
antagonise the expression of one or more inflammatoryThese advanced glycation endproducts have been
shown to promote monocyte adhesion and chemo- response genes at the cytoplasmic transcription factor
or proteasomal level.161,162 Finally, endothelial-leuco-taxis.159,160 Monocyte-macrophages, which are present
at all stages of atherogenesis, may in turn release a cyte adhesion may be modulated by reducing the
systemic leucocyte count by the use of extracorporealnumber of inflammatory cytokines and growth factors
involved in the progression of the atherosclerotic leucocyte filters.
plaque.159
Possible limitations
The temporal and spatial patterns of expression ofTherapeutic Applications
CAM in vivo in various disease states have yet to
be fully characterised, and, therefore, it may not beWhile endothelial-leucocyte adhesion and diapedesis
possible at present to effectively block a particularare necessary for normal host defence, there exist a
CAM in a specific and timely fashion. Furthermore,number of inflammatory diseases in which excessive
the existence of multiple or redundant mechanisms ofor inappropriate leucocyte recruitment contributes to
leucocyte recruitment in particular organs and diseasestissue damage. For example, in atherosclerosis, mono-
may necessitate the simultaneous blockade of multiplenuclear leucocytes accumulate in the arterial wall and
adhesion pathways. For example, in the pulmonarysecrete inflammatory cytokines and growth factors
microcirculation, CD18-dependent and CD18-in-which promote plaque progression. Although the
dependent mechanisms of leucocyte recruitment ap-pathogenesis of atherosclerosis is not fully understood,
pear to operate.163it is believed to be an inflammatory response to in-
Monoclonal antibody (mAb) therapy has certainjurious stimuli.159 Therefore, the ability to inhibit the
theoretical limitations. mAb generated using animalsrecruitment of mononuclear leucocytes may be a way
may induce sensitisation or contain endotoxin or virusof modulating plaque progression. Similarly, res-
contamination. The Fc portion of mAb may mediatetoration of blood flow following a period of limb or
complement activation and non-specific neutrophilorgan ischaemia is characterised by recruitment and
binding once the F(ab¢)2 portion has bound to theactivation of neutrophils which are believed to induce
endothelial target antigen. However, while F(ab¢)2 frag-postischaemic tissue injury during reperfusion. Plate-
ments are able to bind and block the target antigen,let thrombosis occurs by two cell adhesion processes
they have brief plasma half-lives being cleared rel-(platelet adherence and aggregation), both of which
atively rapidly from the circulation. Additionally, inare mediated by platelet integrins and glycoproteins.
animal studies, mAb have been shown not to beAll these disease processes depend on the adhesion
efficacious in reducing leucocyte recruitment unlessand aggregation of leucocytes and platelets to vascular
their efficiency of blockade exceeded 90%.164 Once aendothelium mediated by CAM and chemoattractants.
few neutrophils adhere, these appear able to recruit
other neutrophils, presumably by amplification mech-
anisms (see above).
A theoretical concern of blockade of b2 (CD18)Potential molecular targets
integrins is the possibility of inducing an im-
munocompromised state and uncontrolled sepsis byKnowledge of the cellular and molecular mechanisms
of leucocyte recruitment and platelet thrombosis af- interfering with the ability of neutrophils to ex-
travasate and kill bacteria at sites of infection. Animalfords the possibility of pharmacologically modulating
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Table 3. Molecular targets in the modulation of inflammation and thrombosis.
Target molecule Function Pharmacological agent
Inflammatory cytokines Endothelial and leucocyte activation Monoclonal antibody
Soluble receptor antagonist
Selectins Leucocyte-endothelial initial attachment and rolling Monoclonal antibody
Soluble selectin or ligand
Synthetic carbohydrate
b2 integrins Stable adhesion of leucocytes and diapedesis Monoclonal antibody
Ig Soluble CAM
Soluble counter-receptor
gpIIb/IIIa Platelet aggregation Monoclonal antibody
Platelet integrins Platelet-endothelial adhesion
Chemoattractants Integrin activation and leucocyte recruitment Monoclonal antibody
Chemokines Soluble receptor
Synthetic receptor antagonist
Transcription regulation of mRNA synthesis and protein synthesis of inflammatory Proteasome inhibitors
inflammatory response genes response gene product e.g. E-selectin Antisense oligonucleotides
studies have yielded conflicting results as to whether Platelet thrombosis, restenosis and thrombolysis
CD18-blockade increased septic complications.165,166
The surface exposed by vascular endothelial injury
following balloon angioplasty or ulceration of ath-
erosclerotic plaque is highly thrombogenic. Platelets
adhere to subendothelial matrix proteins such as col-Ischaemia-reperfusion injury
lagen and fibronectin, and then become activated and
degranulate, releasing coagulation proteins, calciumTissue ischaemia may occur in a variety of clinical
ions (necessary for coagulation), ADP (mediates plate-situations including acute vessel occlusion by
let aggregation), and chemokines (e.g. PF4). Activatedthromboembolism, trauma or surgical cross-clamping
platelets may also secrete thromboxane A2, a potentof major vessels, compartment syndrome, autogenous
vasoconstrictor and stimulus of platelet aggregation.muscle transplantation for wound coverage and solid
Low-dose aspirin inhibits the synthesis of throm-organ transplantation. During ischaemia, cellular in-
boxane A2 by irreversibly acetylating the enzyme cyclo-jury is caused by a reduction in the supply of oxygen
oxygenase. As platelets are anuclear cells unable toand nutrients as well as inadequate clearance of prod-
synthesise new proteins, they cannot manufacture newucts of metabolism. Survival of ischaemic tissue is,
enzyme during their short lifespan of just over atherefore, dependent on timely and sufficient res-
week. In contrast, prostacyclin (an inhibitor of platelettoration of its blood supply (reperfusion). However,
aggregation) production by endothelial cells is rel-beyond a certain period of ischaemia, reperfusion may
atively unaffected by low doses of aspirin. Thus, lowitself result in additional damage of postischaemic
dose aspirin tips the balance of prostaglandin meta-tissues and an accelerated rate of necrosis despite
bolism towards inhibition of platelet aggregation.173adequate restoration of blood flow.167,168 Neutrophil
Ticlodipine and clopidogrel are novel antiplateletinfiltration is characteristic of the inflammatory re-
agents which are more potent than aspirin.174 They aresponse to reperfusion following ischaemia.168,169 The
inactive in vitro, but in vivo, after hepatic metabolismpathogenesis of reperfusion injury is complex but is
into their active moieties, they produce irreversiblebelieved to be due in part to neutrophil-mediated
platelet inhibition by selectively blocking ADP re-damage.168,170–172 Both CAM and chemoattractants have
ceptors and inhibiting fibrinogen binding of gpIIb/been shown to mediate neutrophil recruitment in
IIIa.175reperfusion injury.144,164,172 Blockade of CAM and
Following balloon angioplasty of atherosclerotic ves-chemoattractants in numerous animal models of
sels, damage to the intima may induce platelet ac-ischaemia and reperfusion in different organs ap-
tivation and aggregation and thrombosis resulting inpeared to reduce the extent of tissue damage during
acute thrombotic occlusion (termed “abrupt closure”).reperfusion.144,164,168,172 These findings remain to be con-
firmed in clinical studies. Activated platelets may also be a source of growth
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